Literature DB >> 4020069

Redirection of extensor pollicis longus in the treatment of spastic thumb-in-palm deformity.

P R Manske.   

Abstract

Twenty patients with the thumb-in-palm deformity associated with cerebral palsy were treated surgically by redirecting the extensor pollicis longus (EPL) tendon through the first dorsal retinacular compartment in association with releasing the spastic intrinsic thenar muscles at their origin. The redirected EPL tendon augmented extension-abduction of the thumb in all patients; 18 patients were able to grasp with the thumb outside the clenched fist and noted improvement in functional activities. Augmentation tendon transfer that uses the EPL is an ideal surgical treatment for patients with cerebral palsy who have a thumb-in-palm deformity, since the procedure relieves an adduction deforming force and augments the weak extension-abduction by means of a musculotendon transfer that is known to function during digital extension. Consequently, postoperative reeducation of the transfer is minimal.

Entities:  

Mesh:

Year:  1985        PMID: 4020069     DOI: 10.1016/s0363-5023(85)80082-4

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  4 in total

1.  [Neuro-orthopaedic approach to the upper extremity: state-of-the-art surgical procedure].

Authors:  G Manolikaki; C M Schörle
Journal:  Orthopade       Date:  2010-01       Impact factor: 1.087

2.  [The upper extremity in cerebral palsy. OP indications and surgical techniques].

Authors:  G Manolikakis; C M Schörle
Journal:  Orthopade       Date:  2004-10       Impact factor: 1.087

3.  Assessment of the hand in cerebral palsy.

Authors:  Praveen Bhardwaj; S Raja Sabapathy
Journal:  Indian J Plast Surg       Date:  2011-05

4.  Effects of upper extremity surgery on activities and participation of children with cerebral palsy: a systematic review.

Authors:  Annoek Louwers; Jessica Warnink-Kavelaars; Joost Daams; Anita Beelen
Journal:  Dev Med Child Neurol       Date:  2019-07-23       Impact factor: 5.449

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.